Skip to main
INKT
INKT logo

MiNK Therapeutics (INKT) Stock Forecast & Price Target

MiNK Therapeutics (INKT) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MiNK Therapeutics Inc is making significant advancements in the development of innovative therapies utilizing invariant natural killer T (iNKT) cells, which exhibit promising indicators for treating solid tumors and show potential improvements in pro-inflammatory markers that may enhance patient responses. The strategic decision to engage in an externally funded investigator-sponsored trial allows the company to explore new indications without straining its capital resources, bolstering its financial positioning as it expands its development pipeline. Increased operating expenses expected in 2025 are an anticipated investment in the growth of iNKT programs, such as agenT-797 and MiNK-215, which have already demonstrated positive outcomes in tumor progression and immune response enhancements in clinical settings.

Bears say

The analysis identifies multiple fundamental risks associated with MiNK Therapeutics, including potential safety issues and lower-than-expected efficacy from clinical programs, which could significantly impact the company's future performance. Additionally, the anticipated need for substantial financing—estimated at approximately $55 million through 2038—coupled with a cash runway extending only into mid-2025, raises concerns about liquidity and operational sustainability. Furthermore, the company faces the threat of de-listing if its stock price falls below $1, and competition from existing and emerging therapies could undermine its market position.

MiNK Therapeutics (INKT) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MiNK Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MiNK Therapeutics (INKT) Forecast

Analysts have given MiNK Therapeutics (INKT) a Buy based on their latest research and market trends.

According to 4 analysts, MiNK Therapeutics (INKT) has a Buy consensus rating as of Sep 1, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MiNK Therapeutics (INKT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.